



**ISCO3 Clinical Trials Follow-up to the preliminary results about use of O<sub>2</sub>/O<sub>3</sub> in the treatment /prevention of Novel Coronavirus Pneumonia (COVID-19).**

Country Region	Protocol	Remarks / Side effects
<b>BAZIL</b> Dr. Arnaldo De Souza	Studo multicêntrico da prática integrative e complementar de ozonio terapia em pacientes internados com COVID-19. Estudo multicêntrico da prática integrative e complementar de ozonio terapia em pacientes ambulatoriais com COVID-19.	
<b>CHINA</b> Hospital / N patients = 4 FINISHED* Reg. ChiCTR2000030102 Researcher: Huiling Huang. / Location: Tianjin Haihe	MAH 100 mL blood + 100 mL, up-to 200 mL, 1-2 times a day. Critical case 2-4 times a day. Time schedule: 10 d <b>Case report Ready</b>	Patient feels better // Chest tightness is improved ↑ 50 % PaO <sub>2</sub> after the first application <b>S.E.:</b> <b>Allergy</b>
ChiCTR2000030165 Tianjin University ChiCTR2000030006 Union Hospital	control group:30; mild ill patients:15; severe/critical ill patients:15;	
<b>CUBA</b> Hosp. Dr. Salvador Allende, Sponsor: Dr. Rodolfo Suárez OZO-001	Rectal insufflation in SARS-CoV2 hosp. patients	↓ Viral Load in 5 days ↑ Clinic
CNIC (Promotor). Inv. P. Zullyt Zamora R RPCEC00000320	Rectal insufflation in SARS-CoV2 hosp. patients 16 Conventional Therapy / 16 Conventional plus O <sub>3</sub> rectal (20→40 µg/mL, vol 100 → 200 mL, one every 12 h, total 20 sessions)	Improve clinicals symptoms and oxidative stress markets. ↓ Viral Load in 75% of patients in 6 days.
<b>INDIA</b> Dr Mili Shah CTRI/2020/07/026354	n=60 Rectal insufflation and minor auto haemotherapy together with standard of care.	There was improved SPO <sub>2</sub> , clinical symptoms status. There was faster viral eradication from host cells. 77% of subjects from the ozone-treated group were RT-PCR negative on day 5 and 100% subjects were RT-PCR negative on day 10.
CTRI/2020/07/026671 Dr Alok Sharma / Dr Mili Arpan / Dr Jignasha	N=10 O <sub>3</sub> SS	
CTRI/2020/08/027038 Dr. Prabhat Kumar / Dr. Ashish	N=100 Study to assess effects of nano ozonised hydrogen peroxide nebulisation on results of RT-PCR for novel corona Virus thus infectivity and clinical course among mild to moderate sick COVID-19 Patients	
<b>IRAN</b> IRCT20191125045492N2 Bagheiat-allah Univ. of Med. Sci. Staff: Dr. Ali Sarrafzadeh/Dr. Izadi/Dr. Effat Nikfarjam	<b>Moderate</b> MAH 100-200 mL O <sub>3</sub> 1:1 35→45 µg/mL, daily 4 session <b>Severe</b> MAH 200 mL O <sub>3</sub> 1:1 35 →50 µg/mL daily 7 session O <sub>3</sub> water 60 mL every 6 h	Preliminary results (n=14): Clinical improve. CT evidence of improvement Not yet recruiting
IRCT20200616047792N1	Ahvaz University of Medical Sciences	
IRCT20190618043923N4	Ozone Autohemotherapy in Covid19. Tabriz University of Medical Sciences NCT04400006	
<b>ITALY</b> ClinicalTrials.gov <b>NCT04366089</b> N= 152 vs Control. Condition: Mild /Severe Researcher: Fabio Araimo Sponsor: Roberto Poscia M.D., Ph.D.	<b>MAH</b> Proportion of O <sub>2</sub> /O <sub>3</sub> : Blood 1:1. 250 mL O <sub>2</sub> /O <sub>3</sub> 30 µg/mL, every 12 h for 7 days. Location: Hosp. Umberto I. Roma Approval: Hosp. Umberto I /Univ. Sapienza Roma	Preliminary results: Fast ↓ RT-PCR 2019-nCoV. IL-6↓ <b>?</b>
Researcher: Amado del Monte / Carlo Tascini ClinicalTrials.gov Identifier: <b>NCT04388514</b> Location: Hosp. Univ. Santa M. Misericordia / Udine Approval: <b>Pending</b> EC Univ. Friuli	Proportion of O <sub>2</sub> /O <sub>3</sub> : Blood 1:1. MAH 200 mL. O <sub>2</sub> /O <sub>3</sub> 40 µg/mL, 3 times Groups: Antiretroviral therapy (AT) / or AT + O <sub>3</sub> N= 90 treated / two groups of 45	Preliminary outcome: Clinical improvement in 35 /36 patients. Recruiting <b>?</b>
Sponsor: Mariano Franzini // SIOOT Location: 17 Hosp.? N= 73 Approval: <b>?</b>	<b>Mild:</b> MAH blood: 150-200 mL 1:1 O <sub>3</sub> 30/ 40 µg/mL. 2 times a week. Ozonized oil spray 2 times a day. <b>Moderate:</b> MAH blood: 150-200 mL 1:1 O <sub>3</sub> 40/ 50 µg/mL. 3 times a week. Ozonized oil spray 2/3 times a day. Ozonized water 250 mL 3 times a day. <b>Severe / Critical: ?</b>	↑: PaO <sub>2</sub> , clinical symptoms, Renal function, Cardiac frequency, ↓ Fever, ↓PCR, removal of assistant respiration in 5 days. <b>S.E.:</b> 1 death not associated with treatment septic shock
<b>SPAIN</b> EudraCT: 2020-002425-28 N= 50 Preliminary results available Sponsor: AEPRMO. Approved by etic committee 18/05/2020-05/20	O <sub>3</sub> SS 5→3 µg/kg b.w. a day x 10 days Vit.C + GSH 1,2 g i.v. in 100 mL Saline	↓ Fever in 3-4 days ↓ Viral Load in 3-4 days Outcome, Preliminary results: available on Pre-print
ClinicalTrials.gov <b>NCT04359303</b> N=50 Dr. Javier H. Tallón, Univ. Cat. San A. Murcia	MAH O <sub>2</sub> /O <sub>3</sub> : Blood 1:1 200 mL O <sub>3</sub> 40 µg/mL + Base WHO recommended treatment.	Not yet recruiting
ClinicalTrials.gov <b>NCT04370223</b> Researcher: Dr. Alberto Hernández N=10 Location: Hosp N. Señora del Rosario. Ibiza	MAH O <sub>2</sub> /O <sub>3</sub> : Blood 1:1 200 mL 1:1 O <sub>3</sub> 40 µg/mL every 12 h for 5 day, 1 session a day up to 16 sessions. <b>?</b>	↓ Ferritin ↓ d-dimer in 24/48 h ↑ Clinic <b>?</b> Preliminary results available on Pre-print
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta <b>NCT04444531</b>	18 participants. Ozone autohemotherapy plus standard treatment	<b>Completed recruitment</b> No Results Posted
<b>TURKEY</b> <b>Prevention</b> Sponsor: Marmara University // NCT04400006	10 session in 6 months MAH O <sub>2</sub> /O <sub>3</sub> : Blood 1:1 100 mL O <sub>3</sub> 10 -20 µg/mL. 71 participants.	<b>Completed recruitment</b> No Results Posted
<b>USA</b> Researcher: P. Brian Volpp Location: Palomar Med. Center. California	EBOO 7L of blood in 1h, once a week	Protocol approved by IRB

**Legend:** E.C., etic committee; S.E. side effects; IRB, Institutional Review Boards; FIO; New Italian Federation of Ozone Therapy; O3SS, ozonized Saline Solution; MAH, Mayor autohemotherapy; EBOO, Extracorporeal blood oxygenation-ozonation; RIO3, rectal insufflation; SIOOT, Società Scientifica Ossigeno Ozono Terapia; AIRO, Accademia Internazionale di Ricerca in Ossigeno-Ozono Terapia. \* No more patients available, author will write a case report; ? Not confirmation available.